The maker of a drug intended to reduce premature births is making a last-ditch effort to keep its medication on the market, even as health regulators insist that it doesn’t work
This image provided by Covis Pharma shows packaging for the company's Makena medication. Covis, the maker of the only U.S. drug intended to prevent premature births will make a last-ditch effort to keep its medication on the market in October 2022, even as health regulators revisit mounting evidence that it doesn't work. WASHINGTON — — The maker of the only U.S.
About 10% of U.S. births come too early — before 37 weeks, raising the risk of serious health problems and even death in infants. Complicating the Makena debate is support from the leading U.S. obstetrics group to keep the decade-old drug available while more research is done. “Based on the evidence shown today, Makena is not shown to be effective,” said FDA’s drug chief, Dr. Patrizia Cavazzoni, in opening remarks Monday. “Its benefit and risk profile is unfavorable and it should be withdrawn from the market.”, which allows drugs like Makena to launch based on promising early results while additional, usually larger, studies are conducted.
In recent years, the FDA's cancer division has begun prodding companies to stop selling their drugs for uses granted under these so-calledThe FDA approved Makena in 2011 based on a small study suggesting it reduced rates of premature birth in women with a history of early deliveries. Makena consists of a synthetic version of the hormone progesterone, which helps the uterus grow and maintain a pregnancy. Women can start the shots after 16 weeks of pregnancy.
In briefing documents released this month, the FDA said leaving Makena on the market"incurs false hopes, the risks associated with treatment, and other burdens" like excess medical spending. According to a recent
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
The FDA says a drug for preventing preterm births does not work. The drugmaker has pushed back, enlisting support of Black women.Daily News | The FDA says a drug for preventing preterm births does not work. The drugmaker has pushed back, enlisting support of Black women.
Read more »
St. Sabina parishioners rally behind Rev. Michael Pfleger amid new sexual abuse allegationSt. Sabina Church parishioners gathered Sunday morning for a joyful service, pushing back against a newly surfaced sexual abuse claim against their senior pastor, the Rev. Michael Pfleger.
Read more »
Motley Fool: Advanced Micro Devices has been building momentumAdvanced Micro Devices is a promising company in the semiconductor industry, with its price recently pushed down amid the overall market’s pullback. The...
Read more »
FT Journalists Deny Writing FUD in Heated Debate with Bitcoin Reporters | CoinMarketCapFT columnist Jemima Kelly and former Alphaville editor Izabella Kaminska pushed back on the idea that critical articles written about Bitcoin amounted to 'FUD' 👀
Read more »